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Background: Glioblastomas are deadly cancers that display a functional cellular hierarchy maintained by self-
renewing glioma stem cells (GSCs). Self-renewal is a complex biological process necessary for maintaining the
glioma stem cells. Nuclear factor rythroid 2-related factor 2(Nrf2) plays a significant role in protecting cells from
endogenous and exogenous stresses. Nrf2 is a key nuclear transcription factor that regulates antioxidant response
element (ARE)-containing genes. Previous studies have demonstrated the significant role of Nrf2 in the proliferation
of glioblastoma, and in their resistance to radioactive therapies. We examined the effect of knocking down Nrf2 in
GSCs.
Methods: Nrf2 expression was down-regulated by shRNA transinfected with lentivirus. Expression levels of Nestin,
Nrf2, BMI-1, Sox2 and Cyclin E were assessed by western blotting, quantitative polymerase chain reaction (qPCR)
and immunohistochemistry analysis. The capacity for self-renewal in vitro was assessed by genesis of colonies. The
capacity for self-renewal in vivo was analyzed by tumor genesis of xenografts in nude mice.
Results: Knockdown of Nrf2 inhibited the proliferation of GSCs, and significantly reduced the expression of BMI-1,
Sox2 and CyclinE. Knocking down of Nrf2 changed the cell cycle distribution of GSCs by causing an uncharacteristic
increase in the proportion of cells in the G2 phase and a decrease in the proportion of cells in the S phase of the
cell cycle.
Conclusions: Nrf2 is required to maintain the self-renewal of GSCs, and its down-regulation can attenuate the self-
renewal of GSCs significantly.Background
Glioblastoma multiforme (GBM) is a lethal brain tumor.
The median survival is approximately 14 months, even
with aggressive surgery, radi0- and chemotherapy [1,2].
Recent studies have shown that some cells in gliomas
retain many features of neuronal progenitor cells, in-
cluding the ability to grow as neurospheres in culture,
self-renew, and migrate in the brain [3-5]. These cells re-
tain features of neural stem cells (NSCs), and we have
referred to these particular cells as glioma stem cells
(GSCs). They express the NSCs surface markers CD133
and Nestin [6-9]. There are novel opportunities for de-
veloping therapeutics by targeting the differentiation and* Correspondence: hdwang_nz@yahoo.cn
2Department of Neurosurgery in Jinling Hospital, Neurosurgical Institution of
People’s Liberation Army of China, No. 305, East Zhongshan Road, Nanjing,
Jiangsu 210002, China
Full list of author information is available at the end of the article
© 2013 Zhu et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orself-renewal features of glioma. Unfortunately, GSCs are
often resistant to either radio- or chemotherapy [10-12].
Although these cells represent only a small fraction of the
tumor bulk, their high self-renewal capacity is thought to
sustain tumor growth. The signaling pathways that main-
tain the proliferative capacity of these cells offers great
potential for a better understanding of tumor genesis and
development.
Nuclear erythroid-2-related factor 2 (Nrf2) is a redox-
sensitive, basic leucine zipper protein that regulates the
transcription of several antioxidant genes. It is a key
nuclear transcription factor that regulates antioxidant
response element (ARE)-containing genes [13,14]. The
factor regulate gene include GSH synthesis, glutathione
reductase and peroxidase families, NAD(P)H: quinone
oxidoreductase1 (NQO1) [13]. Recent studies have shown
multi-regulating potentials in many steps of cell biology
[15,16]. The anti-tumor effects of Nrf2 were found to be. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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entiation and growth inhibition in vitro [17,18]. However,
the role of Nrf2 cell signaling pathway during self-renewal
of GSCs is unclear. We hypothesize Nrf2 influences
the proliferation of GSCs, which induce the relapse
and invasion of glioblastoma.
In this study, we examined the role of Nrf2 in GSCs-
by knocking down of Nrf2 with short hairpin RNAs
(shRNAs) and decreased the proportion of spheres of
GSCs. The cell cycle distribution of GSCs also changed
with the variation of Nrf2 expressional level. Sox2, BMI-1
and Cyclin E had been identified playing an important
role in self-renewal of GSCs. In our study, we found
these biomarkers down-regulated by knocking down of
Nrf2, which infer the relationships between Nrf2 and
self-renewal. Developing of xenografts in node mice
confirm repression of proliferation when the transcrip-
tion level of Nrf2 decreased by shRNA. Finally, Nrf2
depletion was found to block the proliferation of human
glioma both in vitro and in vivo.
Methods
Experimental procedures
Our study design was approved by the Ethics Committee
of Jinling Hospital (Nanzi20120017). Patients that were
recruited to our study provided written informed con-
sent for participation to permit the scientific using their
samples. Our animal experiments were approved by the
Animal Ethics Committee of the Animal Experiment
center at Jinling Hospital (SCXK 2012-012).
Cell culture and treatment
Primary human glioblastoma G1, G2 and G3 cells were
derived from freshly resected human surgical glioblastoma
specimens. These were obtained from three patients of the
Department of Neurosurgery in Jinling Hospital (Nanjing,
P.R. China) and grown as tumor- spheres as former
reported [19-21]. All samples were identified glioblastoma
(WHO IV) by pathologists of Jinling Hospital. Tumors
were dissociated with 0.25% trypsase and released by gen-
tle pipetting and filtrated through a 70 μm cell strainer.
Adherent culture of cells were performed by plating the
cells in a gelatin-coated plastic flask in DMEM for 24 h
and washed with PBS to remove red blood cells and cell
debris. The tumor cells were collected and seeded in
neural stem cell (NSC) medium (Gibco, USA) which com-
bined Knockout medium with Neural-supplement, human
recombinant basic fibroblast growth factor (bFGF, 50 ng/mL,
Gibco, USA), epidermal growth factor (EGF, 50 ng/mL,
Gibco, USA), penicillin (100 units/mL, Sigma, USA),
streptomycin (100 ug/mL, Sigma, USA), and L-glutamine
(2 mmol/L, Sigma, USA), and the density of 200 cells/cm2
to obtain floating tumor-spheres. Primary GSCs were
incubated at 37°C in a atmosphere containing 5% carbondioxide for 5 to 7 days. The medium was half-renewed
every 3 days. Once cells were greater than 100 um in
diameter, they were tentatively defined as GSCs spheres.
Preparation of the lentivirus
Lentiviruses vectors for expression of Scrambled or Nrf2
shRNA was diluted in NSC medium containing 6 ug/ml
polybrene. The shRNAs were then added to GSC cultures
after 72 hours, transfected cells were selected using puro-
mycin (5 ug/ml) for 24 hours. The human Nrf2 shRNA
sequence was 5′-GCAGTTCAATGAAGCTCAACT-3′,
while the scrambled shRNA sequence was 5′-TTCTCC
GAACGTGTCACGT-3′. The lentivirus vectors were pur-
chased from GenePharma Co., Ltd. (Shanghai, China).
Secondary sphere propagation and sphere formation
assay
To evaluate effects of knocking down of Nrf2 on GSCs
population, primary GSCs were non-infected (control
group) and infected with lentivirus for expression of either
Scrambled or Nrf2 shRNA and selected for puromycin
resistance as above. Following infection, the transduced
cells were seeded into 24-well plates. After 72 hours, cells
were dissociated with Accutase (Sigma-Aldrich, USA) for
15 min and re-seeded into culture dishes (100 mm in
diameter) at a density of around 200 cells/cm2. At
96 hours after re-seeding, the number of sphere-like
colonies was assessed by two independent scorers who
were unaware of the sample designation.
For comparing spheres formation efficiency of colonies,
GSCs were transduced with lentiviral particles as de-
scribed above. At 72 hours after transduction, cells were
dissociated with Accutase (Sigma-Aldrich, USA) and
seeded at a density of 200 cells/cm2 in 24 well plates in
quadruplicate, using culture medium supplemented with
10% fetal bovine serum (FBS). Cells were re-feed every
2 days, and after 2 weeks, cells were stained by gentian
violet. The number of neuronal sphere-like colonies and
differentiated colonies with a diameter greater than 50 um
was counted by two independent scorers.
Western blotting
Total protein lysates were prepared using an immuno-
precipitation cell disruption and nuclear protein prep-
aration kit (Beyotime, China). The cell disruption kit
was supplemented with phenylmethanesulfonyl fluor-
ide (PMSF), a protease inhibitor, and protein concen-
trations determined with a Bradford Protein Assay Kit
(Beyotime, China). Nuclear proteins were separated
using sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS PAGE) on 8–12% gradient gels. Sepa-
rated proteins were transferred onto PVDF membranes
(Millipore, Germany), the membrane was cut into narrow
piece according to the protein molecular massive marker
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at room temperature and probed with the appropriate
antibody. Primary and secondary antibodies were di-
luted in 3% (w/v) bovine serum albumin (BSA) and sec-
ondary antibodies diluted in Tris-buffered saline (TBS)
supplemented with 0.1% Tween 20 (TBST), respectively.
Membranes were incubated with primary antibodies
overnight, at 4°C, and with secondary antibody for
60 minutes, at room temperature. Following incubation
with primary and secondary antibodies, membranes
were washed three times (10 minutes per wash) with
TBST, and developed by incubating in enhanced chemi-
luminescence(ECL)substrate (Millipore, Germany) for
5 minutes at room temperature. The fluorescent signal
was detected with black-white films (Kodak, USA). The
primary antibodies used were against the following
proteins: Nrf2 (1:1000 dilution, Abcam, UK), Cyclin E
(1:1000 dilution, Abcam, UK), Sox2 (1:1000 dilution,
Epitomic, UK), BMI-1 (1:500 dilution, Epitomic, UK),
and Histone H3 (1:500 dilution, Abcam, UK). The
secondary antibody was an anti-rabbit-IgG conjugated
to horseradish peroxidase (HrP) (Bioworld, USA) and
was used at a 1:5,000 dilution.
RNA isolation and qPCR
The GSCs were infected or infected with lentiviruses
vectors expressing either Scrambled or Nrf2 shRNA, as
described above. At 72 post-transduction, RNA was
isolated from three independent cell culture prepara-
tions, and cDNA was synthesized using a Strand cDNA
Synthesis Kit (Takara, Japan). Levels of transcripts for spe-
cific genes were determined by SYBR Green qRT-PCR,
using gene specific primers for human transcripts encod-
ing Nrf2, NQO1, HO-1, Sox2, BMI-1, Cyclin E, Nestin,
GFAP and GAPDH. Primary sequences provided in
supplementary material Table 1.
Cell cycle analysis by flow cytometry
GSCs were seeded at a density of 1 × 106 cells per 100 mm
plate. After 24 hours, cells were infected with Scrambled
or Human Nrf2 shRNA lentiviral constructs, followed by
puromycin selection, as described above. At 72 hours
post-infection, cells were prepared for cell cycle analysis
by using propidium iodide (PI) staining and a Cell Cycle
and Apoptosis Analysis Kit (Beyotime, China), according
to the manufacturer’s protocol. Floating cells were in-
cluded in the GSCs cell cycle analysis. Flow analyses were
performed by the UNMC Cell Analysis core facility.
Immunocytochemistry
GSCs infected with Scrambled or Nrf2 shRNA lentiviruses
were seeded into a 24-well plates, previously coated with
0.1% gelatin or Matrigel, respectively. At 24 hours post-
seeding, wells were washed three times with 500 ul ofPBS. Cells were then fixed with 4% formaldehyde (Sigma-
Aldrich, USA) in PBS for 20 minutes at room temperature.
Cells were washed twice with PBS, permeabilized with
PBS containing 0.1% Triton X-100 in PBS for 10 minutes
at room temperature, and washed three times in PBS,
before blocking. Cells were stained for Nrf2, Sox2, BMI-1,
Cyclin E, Nestin and GFAP and blocked using 5% BSA
(Sigma-Aldrich, USA) in PBS for 1 hour at room
temperature. Following blocking, cells were incubated
with Nrf2, Sox2, BMI-1, Cyclin E mixed with an anti-
Nestin primary antibody overnight, at 4°C on a rocking
platform. Cells were washed three times in PBS and the
appropriate secondary antibody added, then allowed to
incubate for 1 hour in the dark at room temperature. Cells
were then washed three times in PBS, stained with DAPI
and washed twice in PBS. Cells were photographed with
a fluorescence microscope (Cral Ziess, Germany). We
used primary antibodies against: Nrf2 (1:100 dilution,
rabbit polyclone, Abcam, UK), Sox2 (1:200 dilution,
rabbit monoclonal, Abcam, UK), Cyclin E(1:200 dilu-
tion, rabbit monoclonal, Abcam, UK), BMI-1 (1:100
dilution, rabbit monoclonal, Abcam, UK), Nestin (1:100
dilution, biobyte, mouse polyclone, UK). Secondary
antibodies were against mouse-IgG conjugated to FITC
(Sigma-Aldrich, USA), and an anti-rabbit-IgG conjugated
to Cy3 (F0382, Sigma-Aldrich, USA). Nuclei were visualized
using DAPI (Sigma-Aldrich, USA) at 1:10,000 in PBS.
Xenografts
GSCs were maintained in serum-free NSCs medium
containing Scrambled or Nrf2 shRNA lentiviruses for
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staining. Viable cells (2 × 104) were dissociated in 50 μl
of PBS and implanted subcutaneously into the flanks of
male nude mice (4 weeks old, n = 6 mice per group) that
were randomly selected (4 weeks old, n = 6 mice per
group) that were randomly selected and divided into
three groups. After 5 weeks, animals were sacrificed and
xenograft tumors measured and subjected to immuno-
fluorescent analysis. Tumor growth was measured every
week and tumor volume calculated as (length/2) ×
width2. All animal experimental protocols used in this
study were in accordance with Institutional Guidelines
for Animal Experiments and nude mice were maintained
at The Center for Experimental Animals of Nanjing
University.Figure 1 Knockdown of Nrf2 in GSCs causes changes in cell morpholo
the protein levels of Nrf2. (A) Photomicrographs of representative GSC c
control group, neural spheres of Nrf2-downregulated group were smaller t
GSCs after transduction. BMI-1, Sox2, Cyclin E, NQO-1and HO-1 decreased w
changed obviously. (C) Western blot assay of the Nrf2. *: P < 0.05; **: P < 0.0Statistical analysis
Results from all experiments were presented from at
least three independent replicates. We used SPSS10.0
statistical software to analyze results by Student’s t-test
or ANOVA as applicable. Values are presented as the
mean ± standard deviation (SD).
Results
Nrf2 knockdown disrupts self-renewal and pluripotency
of GSCs
To determine how the knockdown of Nrf2 affected the
fate of GSCs, two independent observers unaware of sam-
ple designation counted colonies from 20 randomly se-
lected low-power fields (4× magnification) 96 h after cells
were subcultured (Figure 1A). For both sphere densities,gy, elevation of gene markers of proliferation and reduction in
olonies infected with lentiviral constructs for Scrambled shRNA and
han other two groups. (B) qRT-PCR of RNA transcripts isolated from
ith the knocking down of Nrf2. GFAP increased and Nestin not
1; ***: P < 0.005.
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compared with control cells (Figure 2A and 2B). Following
knockdown of Nrf2 levels in GSCs using multiple shRNA
constructs, we observed that cells lost their characteristic
phenotype and differentiated (Figure 2C and 2D). In GSC
cultures infected with the Scrambled shRNA, there was
an 82.67 ± 7.37% increase in the number of sphere-like
colonies, whereas this was 5.67 ± 3.06% when Nrf2 was
knocked down with Human Nrf2 shRNA (Figure 2D).
There was a significant decrease in the number of
sphere-like colonies (P = 0.0047) and a significant in-
crease in differentiated-like colonies (P = 0.0033) upon
Nrf2 knockdown.
Subcellular localization of pluripotency-associated
markers and the Nrf2-asso- ciated protein after
knockdown of Nrf2
We examined the subcellular localization of Sox2
(Figure 3A), BMI-1 (Figure 3B), Nrf2 (Figure 3C), and
cyclin E (Figure 3D). Both the protein BMI-1, Sox2 and
Cyclin E is required for maintenance of self-renewalFigure 2 Self-renewal and the phenotype of GSCs are disrupted upon
with either Scrambled or Nrf2 shRNA lentiviral constructs. (B) gentian viole
photomicrographs of sphere-like (left) and mixed-differentiated (right) colo
like colonies. The proportion of spheres like colonies is lower in Nrf2-downand proliferation [22,23]. Certain kinds of stem cells
constitutively active Cdk2–cyclin-E complexes and
enhance the proliferation of stem cells. Otherwise, the
activity Nrf2 would been dissociated with Keap1 and
transported into nuclear [13]. We needed to analysis
the markers of self-renewal and the activation of Nrf2.
For this purpose, we conducted immunocytochemistry.
Specifically, GSCs were infected with either Scrambled
or Human Nrf2 shRNA lentiviruses. Following infec-
tion, the transduced cells were selected for puromycin
resistance for 24 hours, subcultured into 24-well plates,
and probed for Nrf2, Sox2, BMI-1 and Cyclin E by im-
munocytochemistry. Nrf2, Sox2, BMI-1 and Cyclin E
proteins were detected within the nucleus of sphere-like
cells 72 h after transduction with Scrambled shRNA
(Figure 1C and Figure 3E). There was a reduction in the
intensity of fluorescence associated with Sox2 (Figure 3A),
BMI-1 (Figure 3B), and cyclin E (Figure 3D) after Nrf2
knockdown. Similarly, Nrf2 levels in the nucleus were
lower in the down-regulated group. All GSCs highly
expressed nestin.Nrf2 knockdown. (A) Photo of cloning efficiency of GSCs transduced
t positive colonies in 20 random 4X field. (C) Representative
nies of cells. (D) Quantification of sphere-like and mixed-differentiated-
regulated group.
Figure 3 (See legend on next page.)
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Figure 3 Immunocytochemistry and western blot assay of Sox2, BMI-1, Nrf2, and CyclinE in GSCs with and without Nrf2 knockdown.
Photomicrographs are arranged from top to bottom as: nuclear staining with DAPI, Nestin and stain for (A) Sox2, (B) BMI-1, (C) Nrf2, and
(D) CyclinE. They were merged in the bottom of the pictures. The scale bar is representative for all photomicrographs. (E) Western blot analyses
of nuclear proteins isolated from GSCs. Protein expression levels, presented in parentheses beneath corresponding bands, were normalized
against a corresponding H3 loading control (data not shown).
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of pluripotency-associated genes
Using qPCR assays, we demonstrated significant decreases
in the expression levels of Sox2, BMI-1 (Figure 1B), and
cyclin E (Figure 1B). In contrast, there was a small in-
crease in the expression level of GFAP (Figure 1B). We
did not observe obvious changes in the expression levels
of nestin (Figure 1B). The number of viable cells that
expanded was dramatically reduced upon knockdown of
Nrf2. This corresponded with our previous observation
that Nrf2 knockdown in GSCs reduces their capacity to
proliferate and self-renew.
Nrf2 knockdown enriches the proportion of cells in G2
phase in GSCs
GSCs were infected with either the Scrambled or Nrf2
shRNA lentivirus and cell cycle analysis was conducted
72 h later (Figure 4). Nrf2 knockdown resulted in a signifi-
cant increase in the proportion of cells in the G2 phase
for the Scrambled (30.8 ± 2.1%) and Nrf2 (46.7 ± 4.5%)
shRNAs (P = 0.042). Additionally, there was a correspond-
ing decrease (7.5 ± 0.41%, P = 0.0009) in the proportion of
cells in the S phase (Figure 4).
Knockdown of Nrf2 attenuates the tumorigenicity of GSCs
in vivo
Animals receiving control GSCs and Scrambled shRNA
developed tumors on day 7, while animals receiving
treated GSCs did not develop tumors until day 14. Fur-
thermore, there was also a difference in tumor volume
upon harvest of xenograft tumor from the Scrambled or
the Nrf2 shRNA lentivirus treated groups. As is shown
in Figure 5A and Figure 5B, procreating GSCs treated
with the Nrf2 shRNA lentivirus resulted in a tumor
volume of 210 ± 57 mm3, compared with a much larger
volume of 1850 ± 260 mm3 in tumors treated with the
Scrambled shRNA, and control tumors (1900 ± 300 mm3;
Figure 5A, B, and C).
Discussion
Recent studies have shown that therapeutic resistance of
glioblastomas is due to the presence of viable GSCs that
confer tumorigenic potential and a survival advantage
against chemotherapy [2,11,24]. This therapeutic resist-
ance is based on many inter- and extra-cell regulatory
systems [2,25,26]. These systems allow GSCs to survive
under adverse conditions, including hypoxia, nutrientdeficiency, radioactive injury, cytotoxicity, and immune
system reactions. Previous studies have demonstrated
the importance of the anti-hypoxia ability of GSCs
[27,28], and predicted the potential of anti-hypoxic cell
signaling systems in promoting tumorigenesis of glio-
blastomas [28-30].
Nrf2, a basic redox-sensitive bZIP transcription factor,
is present under anti-hypoxia conditions by influencing
the transcription of HO-1 and VEGF. It also activates
cytoprotective pathways against oxidative injury, inflam-
mation, and apoptosis via the transcriptional induction
of a large number of self-defense genes involved with
phase II detoxication enzymes and antioxidant stress
enzymes [13,15]. Keap1 negatively regulates Nrf2 activity
through ubiquitin-mediated proteasomal degradation.
This indicates that complete loss of Keap1 activity leads
to constitutive activation of Nrf2 [14,15,31]. High levels
of Nrf2 expression in conjunction with temozolomide
treatment induce cell autophagy in glioblastomas [17].
In our laboratory, Nrf2 cell signals enhanced the prolif-
eration of U251 and U87 glioblastoma cell lines [18].
Recent studies demonstrated that Nrf2, well established
as a global regulator of the oxidative stress response,
plays a regulatory role in several kinds of stem cells such
as hematopoietic stem cells and NSCs [32-35]. Nrf2 reg-
ulates hematopoietic stem cell survival, but this process
may not be dependent upon reactive oxidative species
(ROS). These results also suggest that the NRF2/antioxi-
dant response element signaling pathway has the potential
to induce fetal hemoglobin, indicating that Nrf2 plays a
critical role in stem cells. Taken together, these lines of
evidence demonstrate the important role of GSCs during
self-renewal and during glioblastoma relapses, and the
observations support the idea that a reduction in the Nrf2-
dependent protective response may down-regulate the
self-renewal of GSCs.
Using RNA interference (RNAi) technology, Nrf2 was
knocked down in the GSCs of three patients, and GSC
cloning efficiency was significantly decreased when Nrf2
was knocked down. The BMI-1 gene is a polycomb gene
family transcriptional repressor and a proto-oncogene.
The protein BMI-1 is required for maintaining self-
renewal and proliferation [36]. Sox2 is a member of the
Sox gene family and has been shown to be related to
the sex-determining gene Sry and a regulator of the
FGF-4 gene, which is essential for the self-renewal and
pluripotency of NSCs [22,23]. Some stem cells constitutively
Figure 4 Effects of cell cycle analysis by propidium iodide (PI) staining and flow cytometry is presented. (A) The proportion of cells in G2
phase (30.8 ± 2.1%) and S phase (37.13 ± 3.9%) for the Scrambled shRNA. (B) The proportion of cells in G2 phase (46.7 ± 4.5%) for the Nrf2 shRNA;
(P = 0.042). Additionally, there was a corresponding decrease (7.5 ± 0.41%, P = 0.0009) in the proportion of cells in S phase.
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eration of stem cells. Cyclin E binds to G1 phase Cdk2,
which is required for the transition from the G1 to the S
phase of the cell cycle that determines cell division. In our
study, knocking down of Nrf2 in GSCs leads to decreased
expression levels of pluripotency-associated transcriptionfactors such as BMI-1, Sox2 and cyclin E, and an increase
in the expression of markers associated with astrocyte
development.
In our work we showed that transient exposure of
GSCs to Nrf2 shRNAs ex vivo was capable of inhibiting
tumorigenicity in nude mice. We inferred that the Nrf2
Figure 5 Knockdown of Nrf2 attenuates the tumorigenicity of GSCs in vivo. (A) The differences in tumor volume upon harvest of xenograft
tumor from the Scrambled or the Nrf2 shRNA lentivirus treated groups in node mices. (B) morphology of tumors in the node mices. (C) curve of
tumor volume in node mices. procreating GSCs treated with Nrf2 shRNA lentivirus resulted in tumor volume of 210 ± 57 mm3, compared with a
much larger volume of 1850 ± 260 mm3 in scrambled tumors and 1900 ± 300 mm3 in control tumors.
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in vivo and in vitro. Knocking down Nrf2 expression re-
duced the capacity of self-renewal and tumorigenesis
in vivo. Nrf2 may be a potential target for controlling the
growth of glioblastomas in patients.
Our studies also demonstrate a significant enrich-
ment in the proportion of cells in the G2–M phase of
the cell cycle. We also observed a significant decrease
in S-phase cells when Nrf2 was knocked down in
GSCs. The cell cycle of most somatic cells is regulated
by the G1 checkpoint that restricts the G1–S transition
until the formation of activated cyclin-dependent ki-
nases [37]. Certain stem cells lack a G1 restriction
point because of a constitutively active Cdk2–cyclin-E
complex. Both stem cells and somatic cells possess a
checkpoint between the G2 and M phases of the cell
cycle. In the case of GSCs, cyclin E levels oscillate;
when active Cdk2–cyclin E complexes form, the cells
are able to enter M phase. Therefore it is not a surprise
that cell cycle defects in GSCs lead to an accumulation
of cells in the G2–M phases.It is conceivable that Nrf2 plays more than one essen-
tial role in GSCs. To date, a diverse set of biological
functions have been described for Nrf2. It is a key nu-
clear transcription factor that regulates ARE-containing
genes [13,31]. Knocking down Nrf2 expression decreases
the self-renewing activity of GSCs, thereby suggesting
that it plays an important role in regulating GSC prolif-
eration. Recent studies suggest that many factors, in-
cluding Nrf2, influence the self-renewal of stem cells,
the cyto-construction system [38,39], the cell cycle and
check point-related proteins, transcriptional factors [36],
cell growth factors [40,41], adhesion molecules [42,43],
chemotactic factors [44,45], and inter-cell signal trans-
duction pathways [46,47]. In general, Nrf2 is transferred
into the nucleus and binds to certain regions of DNA in
a sequence-independent manner [13]. These regions can
contain the promoter of self-renewal-related molecules
[13,14]. Reactive oxygen species (ROS) act as intracellular
signaling molecules during anti-oxygen processes. Cellular
protective mechanisms against oxidative stress include
transcriptional control of cytoprotective enzymes by Nrf2.
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candidates for determining the possible mechanisms of
Nrf2 during GSC self-renewal. BMI-1 is an important
transcription regulatory factor in stem cells. Sox2 regulates
the secretion of many growth factors such as FGF and
Oct4. Cyclin E is a check point protein, which restricts the
cell cycle in GSCs. Both western blotting and qPCR assays
verified the decrease of these factors through Nrf2
knockdown.
In this study we did not explore the molecular mecha-
nisms of Nrf2 in regulating the self-renewal of GSCs. We
did not discuss the cross-reactivity of Nrf2, BMI-1, Sox2
and cyclin E, or even their relationship to ROS. In a
further study, we will attempt to explore the relationships
between these factors and elucidate the mechanisms of
the Nrf2 cell signaling pathway in regulating self-renewal.
In conclusion, we have demonstrated that Nrf2 contrib-
utes to maintaining self-renewal in GSCs. Identification of
additional proteins that associate with master regulators of
the GSC fate will continue to reveal crucial mechanisms
and machinery driving the fundamental process of self-
renewal. Future efforts to develop cell-based therapies for
glioblastomas will no doubt benefit from advances in
the basic understanding of the molecular machinery
that controls the fate of GSCs.
Conclusions
Nrf2 is required to maintain the self-renewal of GSCs.
Down regulating of Nrf2 by lentivirus can attenuate the
self-renewal of GSCs significantly.
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